Results 221 to 230 of about 6,579 (240)
Some of the next articles are maybe not open access.
Transarterial Radioembolization in Hepatocellular Carcinoma
2021Hepatocellular carcinoma (HCC) is the most common primary liver tumor and fourth most common cause of cancer-related deaths worldwide. For early-stage HCC patients, liver transplantation (LT) is the best choice because it reduces new HCC lesions due to the treatment of liver cirrhosis.
Ramazan Kutlu +2 more
openaire +1 more source
Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma
Abdominal Radiology, 2021Transarterial radioembolization with yttrium-90 microspheres is an established therapy for hepatocellular carcinoma. Post-procedural imaging is important for the assessment of both treatment response and procedural complications. A variety of challenging treatment-specific imaging phenomena complicate imaging assessment, such as changes in tumoral size,
Zersenay Alem +7 more
openaire +2 more sources
Transarterial Radioembolization to Impact Liver Volumetry: When and How
CardioVascular and Interventional Radiology, 2022Inadequate volume of the future liver remnant (FLR) renders many patients with liver malignancies not amenable to surgical resection. Depending on the health of the liver and the patient in general, an FLR of 25-40% is required to avoid acute post-hepatectomy liver failure.
Arash Najafi, Christoph A. Binkert
openaire +2 more sources
Role of nanoparticles in transarterial radioembolization with glass microspheres
Annals of Nuclear Medicine, 2022Transarterial Radioembolization (TARE) with 90Y-loaded glass microspheres is a locoregional treatment option for Hepatocellular Carcinoma (HCC). Post-treatment 90Y bremsstrahlung imaging using Single-Photon Emission Tomography (SPECT) is currently a gold-standard imaging modality for quantifying the delivered dose. However, the nature of bremsstrahlung
Asra Sadat, Talebi +2 more
openaire +2 more sources
Journal of Vascular and Interventional Radiology, 2020
To compare the manifestations of chronic liver injury following transarterial chemoembolization with those of transarterial radioembolization (TARE) in patients with neuroendocrine tumor (NET).This study consisted of an Institutional Review Board-approved single-institution retrospective analysis of NET patients who received transarterial ...
Brian M, Currie +6 more
openaire +2 more sources
To compare the manifestations of chronic liver injury following transarterial chemoembolization with those of transarterial radioembolization (TARE) in patients with neuroendocrine tumor (NET).This study consisted of an Institutional Review Board-approved single-institution retrospective analysis of NET patients who received transarterial ...
Brian M, Currie +6 more
openaire +2 more sources
Transarterial Radioembolization: Patient Selection and Microsphere Characteristics
Digestive Disease Interventions, 2021AbstractTransarterial radioembolization (TARE) using yttrium-90 (90Y)-labeled microspheres has become increasingly adopted as an important treatment option for primary and metastatic hepatic malignancies. Rigorous patient evaluation and selection prior to TARE is critical to optimize the benefits of this therapy and minimize adverse events.
openaire +1 more source
Abdominal Radiology, 2021
Infiltrative-appearance hepatocellular carcinoma presents a challenge to clinicians as diagnostic criteria continue to evolve and evidence-based treatment guidelines have yet to be established. While transarterial radioembolization has shown efficacy in hepatocellular carcinoma, many studies exclude infiltrative-appearance HCC in their analysis.
Michael J. Nisiewicz +5 more
openaire +2 more sources
Infiltrative-appearance hepatocellular carcinoma presents a challenge to clinicians as diagnostic criteria continue to evolve and evidence-based treatment guidelines have yet to be established. While transarterial radioembolization has shown efficacy in hepatocellular carcinoma, many studies exclude infiltrative-appearance HCC in their analysis.
Michael J. Nisiewicz +5 more
openaire +2 more sources
American Journal of Gastroenterology, 2023
INTRODUCTION: The efficacy and safety of combined immunotherapy and transarterial radioembolization (TARE) were suggested in preclinical and early-phase trials, but these were limited by small sample sizes. We sought to compare the efficacy of combined therapy and immunotherapy alone in patients with advanced hepatocellular ...
Yee Hui Yeo +18 more
openaire +2 more sources
INTRODUCTION: The efficacy and safety of combined immunotherapy and transarterial radioembolization (TARE) were suggested in preclinical and early-phase trials, but these were limited by small sample sizes. We sought to compare the efficacy of combined therapy and immunotherapy alone in patients with advanced hepatocellular ...
Yee Hui Yeo +18 more
openaire +2 more sources
Transarterial Radioembolization (TARE)
2018Transarterial radioembolization (TARE) refers to the delivery of radioactive microspheres directly into an artery that perfuses a tumor or tumor-bearing tissue. In current clinical practice, radioembolization is employed almost exclusively for liver tumors, which include primary liver tumors such as hepatocellular carcinoma, as well as metastatic ...
Ryan Hickey +2 more
openaire +1 more source
[Transarterial radioembolization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Der Radiologe, 2022Since the first version of the S3 guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC) in 2013, a large number of studies have consolidated the data on transarterial radioembolization (TARE) and created a broad evidence base.
Thomas, Helmberger, Philippe L, Pereira
openaire +1 more source